DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
ABX-IL8
2
Antibody
Investigational
Unknown
Unknown
Bronchitis, Chronic
Interleukin-8 inhibitor
ABX-IL8
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DAZODALIBEP
2
Protein
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
CD40 ligand antagonist
DAZODALIBEP
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-7160
2
Antibody
Investigational
Unknown
Unknown
Unknown
Epidermal growth factor receptor erbB1 antagonist
RG-7160
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GOLD
2
Small molecule
Investigational
Unknown
Unknown
Amyotrophic Lateral Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Parkinson Disease
Unknown
GOLD
×
Maximum Phase:
2
First Approval:
None
UNII:
79Y1949PYO
Molecule Type:
Small molecule
Molecular Formula:
Au
Molecular Weight:
196.97
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
PF-06650833
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PF-06650833
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VARLILUMAB
2
Antibody
Investigational
Unknown
Unknown
Astrocytoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Lymphoma; Oligodendroglioma; Urogenital Neoplasms; Cholangiocarcinoma; Glioblastoma; Melanoma
CD27 antigen agonist
VARLILUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
0125DUV5XC
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BIIB059
2
Antibody
Investigational
Unknown
Unknown
Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
C-type lectin domain family 4 member C inhibitor
BIIB059
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG3487
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Schizophrenia
Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist
RG3487
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TC99M-MARACICLATIDE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
TC99M-MARACICLATIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROSTAFUROXIN
2
Small molecule
Investigational
Unknown
Unknown
Essential Hypertension; Hypertension
Unknown
ROSTAFUROXIN
×
Maximum Phase:
2
First Approval:
None
UNII:
P848LCX62B
Molecule Type:
Small molecule
Molecular Formula:
C23H34O4
Molecular Weight:
374.52
AlogP:
3.99
PSA:
73.83
HBD:
3.0
HBA:
#RotB:
1.0
Source:
POLY-ICLC
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
POLY-ICLC
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NAVOCAFTOR
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis
Unknown
NAVOCAFTOR
×
Maximum Phase:
2
First Approval:
None
UNII:
W2F2XU189O
Molecule Type:
Small molecule
Molecular Formula:
C15H11F3N4O5S
Molecular Weight:
416.34
AlogP:
1.94
PSA:
141.43
HBD:
2.0
HBA:
#RotB:
5.0
Source:
CALCITONIN EEL
2
Protein
Investigational
Unknown
Unknown
Hemiplegia
Unknown
CALCITONIN EEL
×
Maximum Phase:
2
First Approval:
None
UNII:
R5527T0R0U
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VIXARELIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Oncostatin-M-specific receptor subunit beta inhibitor
VIXARELIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
W25GO3A75W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VISNADINE
2
Small molecule
Investigational
Unknown
Unknown
Cardiovascular Diseases
Unknown
VISNADINE
×
Maximum Phase:
2
First Approval:
None
UNII:
0RL4V0K263
Molecule Type:
Small molecule
Molecular Formula:
C21H24O7
Molecular Weight:
388.42
AlogP:
3.53
PSA:
92.04
HBD:
0.0
HBA:
#RotB:
4.0
Source:
BASIMGLURANT
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Depressive Disorder, Major; Fragile X Syndrome
Metabotropic glutamate receptor 5 modulator
BASIMGLURANT
×
Maximum Phase:
2
First Approval:
None
UNII:
3110E3AO8S
Molecule Type:
Small molecule
Molecular Formula:
C18H13ClFN3
Molecular Weight:
325.77
AlogP:
4.08
PSA:
30.71
HBD:
0.0
HBA:
#RotB:
1.0
Source:
EX-527
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
EX-527
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C13H15ClN2O
Molecular Weight:
250.73
AlogP:
2.5
PSA:
55.12
HBD:
2.0
HBA:
#RotB:
1.0
Source:
SR-123781A
2
Unknown
Investigational
Unknown
Unknown
Coronary Artery Disease; Venous Thromboembolism
Unknown
SR-123781A
×
Maximum Phase:
2
First Approval:
None
UNII:
V952P6826M
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
URELUMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Gliosarcoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Pancreatic Neoplasms; Leukemia; Melanoma
Tumor necrosis factor receptor superfamily member 9 agonist
URELUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
230902QLLC
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
THYMOSIN BETA 4
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
THYMOSIN BETA 4
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DUSIGITUMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Neoplasms; Breast Neoplasms
Insulin-like growth factor II inhibitor
DUSIGITUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
0Z70DT5PRX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SUFUGOLIX
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Gonadotropin-releasing hormone receptor antagonist
SUFUGOLIX
×
Maximum Phase:
2
First Approval:
None
UNII:
56S17Z6X9M
Molecule Type:
Small molecule
Molecular Formula:
C36H31F2N5O4S
Molecular Weight:
667.74
AlogP:
6.52
PSA:
97.6
HBD:
2.0
HBA:
#RotB:
10.0
Source:
APOLIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma
Human leukocyte antigen DR beta chain inhibitor
APOLIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
G88KCP51RE
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TCN-032
2
Antibody
Investigational
Unknown
Unknown
Influenza, Human
Matrix protein 2 inhibitor
TCN-032
×
Maximum Phase:
2
First Approval:
None
UNII:
YFU0W3IJ7E
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BAVISANT
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Attention Deficit Disorder with Hyperactivity
Histamine H3 receptor antagonist
BAVISANT
×
Maximum Phase:
2
First Approval:
None
UNII:
9827P7LFVH
Molecule Type:
Small molecule
Molecular Formula:
C19H27N3O2
Molecular Weight:
329.44
AlogP:
1.44
PSA:
36.02
HBD:
0.0
HBA:
#RotB:
4.0
Source:
METELIMUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Transforming growth factor beta-1 inhibitor
METELIMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
4AR6718OL0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CREATININE
2
Small molecule
Investigational
Unknown
Unknown
Amyotrophic Lateral Sclerosis
Unknown
CREATININE
×
Maximum Phase:
2
First Approval:
None
UNII:
AYI8EX34EU
Molecule Type:
Small molecule
Molecular Formula:
C4H7N3O
Molecular Weight:
113.12
AlogP:
-1.23
PSA:
58.69
HBD:
1.0
HBA:
#RotB:
0.0
Source:
USISTAPIDE
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2; Obesity
Unknown
USISTAPIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
73YSY3U094
Molecule Type:
Small molecule
Molecular Formula:
C34H31F3N2O3
Molecular Weight:
572.63
AlogP:
7.72
PSA:
58.64
HBD:
1.0
HBA:
#RotB:
7.0
Source:
LANOPEPDEN
2
Small molecule
Investigational
Unknown
Unknown
Infections
Unknown
LANOPEPDEN
×
Maximum Phase:
2
First Approval:
None
UNII:
12M6KFD07E
Molecule Type:
Small molecule
Molecular Formula:
C22H34FN7O4
Molecular Weight:
479.56
AlogP:
0.93
PSA:
123.16
HBD:
3.0
HBA:
#RotB:
9.0
Source:
SU-014813
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Breast Neoplasms
Platelet-derived growth factor receptor inhibitor
SU-014813
×
Maximum Phase:
2
First Approval:
None
UNII:
ZZ6VH5MZ17
Molecule Type:
Small molecule
Molecular Formula:
C23H27FN4O4
Molecular Weight:
442.49
AlogP:
1.69
PSA:
106.69
HBD:
4.0
HBA:
#RotB:
6.0
Source:
CLEMIZOLE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CLEMIZOLE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VERUCERFONT
2
Small molecule
Investigational
Unknown
Unknown
Adrenal Hyperplasia, Congenital; Phobia, Social; Alcoholism; Depressive Disorder, Major; Irritable Bowel Syndrome; Stress Disorders, Post-Traumatic
Corticotropin releasing factor receptor 1 antagonist
VERUCERFONT
×
Maximum Phase:
2
First Approval:
None
UNII:
X60608B091
Molecule Type:
Small molecule
Molecular Formula:
C22H26N6O2
Molecular Weight:
406.49
AlogP:
4.58
PSA:
90.37
HBD:
1.0
HBA:
#RotB:
6.0
Source:
ABP-700
2
Small molecule
Investigational
Unknown
Unknown
Unknown
GABA-A receptor; anion channel agonist
ABP-700
×
Maximum Phase:
2
First Approval:
None
UNII:
LZ0835OW2M
Molecule Type:
Small molecule
Molecular Formula:
C17H18N2O4
Molecular Weight:
314.34
AlogP:
2.35
PSA:
70.42
HBD:
0.0
HBA:
#RotB:
5.0
Source:
IC14
2
Antibody
Investigational
Unknown
Unknown
Amyotrophic Lateral Sclerosis; Dengue; Respiratory Distress Syndrome; Severe Acute Respiratory Syndrome
Monocyte differentiation antigen CD14 inhibitor
IC14
×
Maximum Phase:
2
First Approval:
None
UNII:
23IQ3PO968
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NGD-8243
2
Small molecule
Investigational
Unknown
Unknown
Pain
Vanilloid receptor antagonist
NGD-8243
×
Maximum Phase:
2
First Approval:
None
UNII:
K3S4K8ACHE
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
164
165
166
167
168
169
170
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA